Dr. Patrick Frankham reports
PIVOT PHARMA BEGINS PRODUCTION OF 100,000 UNITS OF CBD SOLUTION FOR SALE IN THE EU MARKET
Pivot Pharmaceuticals Inc. has placed an initial production order for 100,000 units of micellized CBD (cannabidiol) solution with SolMic GmbH, a Dusseldorf-based developer and manufacturer of nutraceuticals, cosmeceuticals and pharmaceuticals. Pivot will market and sell the product through its distribution partners in European Union countries, where regulations permit.
Pivot's micellized CBD oral solution is a revolutionary product for the emerging cannabis industry. It contains high-quality and pure extracts of natural hemp oil with a CBD content greater than 99.0 per cent and tetrahydrocannabinol content less than 0.2 per cent. Using patented Micelle technology, the resulting 1-per-cent solution is very effective as it has greatly increased bioavailability (up to 15 times higher than competing products) providing consumers greater consistency and effectiveness.
SolMic's chief executive officer, Dr. Wolfgang Schoenfeld, stated: "The entire SolMic team is thrilled to be working with Pivot Pharma. Production of the miCelleBD oral solution has been initiated and our sales and marketing team has begun to take orders from clients, including from a network of 2,000 pharmacies in Germany and Switzerland. We are very proud of the products made using our patented Micelle technology and consumers will finally be able to purchase a superior bioavailable non-oil oral solution that is highly effective and stable."
Pivot's chief executive officer, Dr. Patrick Frankham, stated: "This initial order is the culmination of 18 months of work between the SolMic and Pivot teams. SolMic has been relentless in its efforts to create a product that has no equal in the marketplace. We look forward to introducing the Pivot Naturals miCelleBD oral solutions to consumers in the EU with the help of SolMic's sales and marketing team and other distribution partners. Pivot intends to introduce other products based on SolMic's patented Micelle technology, including cosmetics and topical creams and gels in the near term."
About Pivot Pharmaceuticals Inc.
Pivot Pharmaceuticals Inc. is a science-based consumer packaged goods cannabis company engaged in the development and commercialization of health and wellness products using innovative, patent-protected drug delivery technologies. Upon receipt of a standard processor licence (pending) from Health Canada, Pivot's premium, bioavailable, stable and effective products will be manufactured at its 50,000-square-foot cyclic good manufacturing practice facility located in Montreal, Que.
We seek Safe Harbor.
© 2020 Canjex Publishing Ltd. All rights reserved.